Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan

Sexually Transmitted Infections

Volumn 85, Issue SUPPL. 2, 2009, Pages

  Vickerman, P ^a   Platt, L ^a   Hawkes, S ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMPARTMENT MODEL; DISEASE TRANSMISSION; DRUG USE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INJECTING DRUG USER; NEEDLE; NONHUMAN; PAKISTAN; PREVALENCE; PRIORITY JOURNAL; BIOLOGICAL MODEL; DRUG ABUSE; EPIDEMIC; EPIDEMIOLOGY; HIGH RISK BEHAVIOR; SUBSTANCE ABUSE;

DISEASE OUTBREAKS; EPIDEMIOLOGIC METHODS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MODELS, BIOLOGICAL; NEEDLE SHARING; PAKISTAN; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 65649128152     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.2008.034660     Document Type: Article

References (55)

1. Joint United Nations Program on AIDS (UNAIDS). AIDS epidemic update. Geneva: UNAIDS, 2008.
2. World Health Organization (WHO). Hepatitis C fact sheet. Geneva: WHO, 2000. http://www.who.int/mediacentre/factsheets/fs164/en/.
3. Baggaley RF, Boily MC, White RG, et al. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006;20:805-12. (Pubitemid 43731561)
4. De Carli G, Puro V, Ippolito G. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003;31(Suppl 2):22-7. (Pubitemid 38186792)
5. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007;18:352-8. (Pubitemid 47374507)
6. Micallef JM, Kaldor J, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
7. Limburg W. Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview. In: Jager JC, Limburg W, Kretzschmar M, et al, eds. Hepatitis C and injecting drug use: impact, costs and policy options. Lisbon: European Monitoring Centre for Drugs and Drug Addiction, 2004:21-40.
8. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999;13:1807-18. (Pubitemid 29509539)
9. Gibson DR, Flynn N, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001;15:1329-41. (Pubitemid 32662285)
10. van den Berg C, Smit C, Van Brussel G, et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam cohort studies among drug users. Addiction 2007;102:1454-62. (Pubitemid 47246988)
11. Goldberg D, Burns S, Taylor A, et al. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scand J Infect Dis 2001;33:457-61. (Pubitemid 32611425)
12. Des Jarlais DC, Perlis T, Arasteh K, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005;19(Suppl 3):S20-5.
13. Kuo I, Ul-Hasan S, Galai N, et al. High HCV seroprevalence and HIV drug use risk behaviors among injection drug users in Pakistan. Harm Reduct J 2006;3:26.
14. Atlaf A, Ali Shah S, Zaidi N, et al. HIgh risk behaviours of injection drug users registered with harm reduction programmes in Karachi, Pakistan. Harm Reduct J 2007;4:1-8.
15. Achakzai M, Kassi M, Kasi PM. Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistran. Trop Doct 2007;37:43-4.
16. Shah SA, Altaf A, Mujeeb SA, et al. An outbreak of HIV infection among injection drug users in a small town in Pakistan: potential for national implications. Int J STD AIDS 2004;15:209. (Pubitemid 38392118)
17. Ur Rehman N, Emmanuel F, Akhtar S. HIV transmission among drug users in Larkana, Pakistan. Trop Doct 2007;37:58-9. (Pubitemid 46440350)
18. National AIDS Control Program. HIV second generation surveillance in Pakistan. National Report Round 1. Canada-Pakistan HIV/AIDS surveillance project, 2005.
19. National AIDS Control Program. HIV second generation surveillance in Pakistan. National Report Round 2. Canada-Pakistan HIV/AIDS surveillance project, 2007.
20. Platt L, Vickerman P, Collumbien M, et al. Prevalence of HIV, HCV and sexually transmitted infections among injecting drug users in Rawalpindi and Abbottobad, Pakistan. Sex Transm Infect 2009;85(Suppl II):ii17-ii22.
21. Mumtaz S, Ur Rehman M, Muzaffar M, et al. Frequency of seropositive blood donors for hepatitis B, C and HIV viruses in railway hospital Rawalpindi. Pak J Med Res 2002;41.
22. Vickerman P, Hickman M, Judd A. Modelling the impact of hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007;36:396-405. (Pubitemid 47062861)
23. Micallef JM, Macdonald V, Jauncey M, et al. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users. J Viral Hepat 2007;14:413-8. (Pubitemid 46744050)
24. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008;93:148-54. (Pubitemid 350236602)
25. Grebely J, Conway B, Raffa JD, et al. Hepatitis C virus reinfection in injection drug users. Hepatology 2006;44:1139-45. (Pubitemid 44748365)
26. Aitken CK, Tracy SL, Revill P, et al. Consecutive infections and clearances of different hepatitis C virus genotypes in an injecting drug user. J Clin Virol 2008;41:293-6.
27. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005;40(Suppl 5):S336-8.
28. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001;26:340-4. (Pubitemid 32435998)
29. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001;26:466-72. (Pubitemid 32489026)
30. Fishbein DA, Lo Y, Netski D, et al. Predictors of hepatitis C virus RNA levels in a prospective cohort study of drug users. J Acquir Immune Defic Syndr 2006;41:471-6.
31. Thomas DL, Astemborski J, Vlahov D, et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis 2000;181:844-51. (Pubitemid 30194464)
32. Thomas DL, Rich JD, Schuman P, et al. Multicenter evaluation of hepatitis C RNA levels among female injection drug users. J Infect Dis 2001;183:973-6. (Pubitemid 32207068)
33. Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) coinfection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 2003;32:727-34. (Pubitemid 37304630)
34. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007;18:437-43. (Pubitemid 47381422)
35. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83. (Pubitemid 34457766)
36. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-6. (Pubitemid 30484478)
37. National AIDS Control Program. Integrated biological and behavioural surveillance: a pilot study in Karachi and Rawalpindi. Canada-Pakistan HIV/AIDS surveillance project, 2005.
38. Smyth BP, Barry J, Keenan E. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Int J Epidemiol 2005;34:166-72. (Pubitemid 40347389)
39. Des Jarlais DC, Perlis T, Arasteh K, et al. "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001. J Acquir Immune Defic Syndr 2004;35:158-66.
40. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002;155:645-53. (Pubitemid 34246097)
41. Hunter GM, Donoghoe MC, Stimson GV, et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS 1995;9:493-501.
42. Kretzschmar M, Wiessing L. New challenges for mathematical and statistical modeling of HIV and hepatitis C virus in injecting drug users. AIDS 2008;22:1527-37.
43. Buse K, Lalji N, Mayhew SH, et al. Political feasibility of scaling-up five evidence-informed HIV interventions in Pakistan: a policy analysis. Sex Transm Infect 2009;85(Suppl II):ii37-ii42.
44. Pilcher CD, Price MA, Hoffman IF, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004;18:517-24. (Pubitemid 38365880)
45. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;342:921-9. (Pubitemid 30177052)
46. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005;191:1403-9. (Pubitemid 40563350)
47. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004;189:1785-92. (Pubitemid 38657214)
48. Grover G, Shivraj SO. Survival pattern of reported HIV infected individuals in the city of Delhi (India). J Commun Dis 2004;36:83-92. (Pubitemid 41673799)
49. Kumarasamy N, Solomon S, Flanigan TP, et al. Natural history of human immunodeficiency virus disease in southern India. Clin Infect Dis 2003;36:79-85. (Pubitemid 36099101)
50. Abdala N, Crowe M, Tolstov Y, et al. Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions. Substance Use and Misuse 2004;39:581-600. (Pubitemid 38501290)
51. Yazdanpanah Y, De Carli G, Migueres B, et al. Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 2005;41:1423-30. (Pubitemid 41579983)
52. Cox AL, Netski DM, Mosbruger T, et al. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005;40:951-8. (Pubitemid 40418300)
53. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002;36:993-1000.
54. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008;93:141-7. (Pubitemid 350245718)
55. Kapadia F, Vlahov D, Des Jarlais DC, et al. Does bleach disinfection of syringes protect against hepatitis C infection among young adult injection drug users? Epidemiology 2002;13:738-41.